Immunocellular Therapeutics Revenue vs. EBITDA

IMUC -  USA Stock  

USD 0.51  0.09  15.00%

For Immunocellular Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunocellular Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunocellular Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunocellular Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunocellular Therapeutics over time as well as its relative position and ranking within its peers. Please see Risk vs Return Analysis.

Immunocellular Current Profitability Trends 

As of December 7, 2021, Price to Sales Ratio is expected to decline to 40.51. In addition to that, Return on Sales is expected to decline to -8.5. As of December 7, 2021, Consolidated Income is expected to decline to about (13.9 M). In addition to that, Net Income is expected to decline to about (13.9 M).
Is Immunocellular Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunocellular Therapeutics. If investors know Immunocellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunocellular Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunocellular Therapeutics is measured differently than its book value, which is the value of Immunocellular that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocellular Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immunocellular Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocellular Therapeutics' market value can be influenced by many factors that don't directly affect Immunocellular Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocellular Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunocellular Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocellular Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Immunocellular Therapeutics EBITDA vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Immunocellular Therapeutics's current stock value. Our valuation model uses many indicators to compare Immunocellular Therapeutics value to that of its competitors to determine the firm's financial worth.
Immunocellular Therapeutics is rated second overall in revenue category among related companies. It is currently regarded as number one stock in ebitda category among related companies . Immunocellular Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at (12.04 Million). Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunocellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunocellular Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunocellular Therapeutics' earnings, one of the primary drivers of an investment's value.

Immunocellular Revenue vs. Competition

Immunocellular Therapeutics is rated second overall in revenue category among related companies. Market size based on revenue of Biotechnology industry is currently estimated at about 637,000. Immunocellular Therapeutics totals roughly 300,000 in revenue claiming about 47% of stocks in Biotechnology industry.

Immunocellular EBITDA vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Immunocellular Therapeutics 
Money Received 
Discounts and Returns 
300 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Immunocellular Therapeutics 
Basic Expenses 
(6.07 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Immunocellular Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Immunocellular Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunocellular Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Immunocellular Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Immunocellular Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for 2021
Consolidated Income-12.9 M-13.9 M
Net Income-12.9 M-13.9 M
Net Income Common Stock-15.9 M-17.2 M
Operating Income-19 M-20.5 M
Preferred Dividends Income Statement Impact3.9 M3.6 M
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 3 people.

Immunocellular Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Immunocellular Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunocellular Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunocellular Therapeutics' important profitability drivers and their relationship over time.

Use Immunocellular Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocellular Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocellular Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Immunocellular Therapeutics Pair Trading

Immunocellular Therapeutics Pair Trading Analysis

Correlation analysis and pair trading evaluation for Immunocellular Therapeutics and Brickell Biotech. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  

Use Investing Themes to Complement your Immunocellular Therapeutics position

In addition to having Immunocellular Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Services Thematic Idea Now

Services Theme
Companies involved in delivering services to business or consumers across different industries and sectors. Services theme has 30 constituents.
View All  Next Launch Services
Please see Risk vs Return Analysis. Note that the Immunocellular Therapeutics information on this page should be used as a complementary analysis to other Immunocellular Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Immunocellular Stock analysis

When running Immunocellular Therapeutics price analysis, check to measure Immunocellular Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocellular Therapeutics is operating at the current time. Most of Immunocellular Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immunocellular Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunocellular Therapeutics' price. Additionally, you may evaluate how the addition of Immunocellular Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
CEO Directory
Screen CEOs from public companies around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
To fully project Immunocellular Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunocellular Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunocellular Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Immunocellular Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Immunocellular Therapeutics investors may work on each financial statement separately, they are all related. The changes in Immunocellular Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunocellular Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.